• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童用伊马替尼口服制剂的设计与稳定性。

Design and stability of pediatric oral formulation of imatinib.

机构信息

Pharmacie, Hôpital Universitaire Necker - Enfants Malades, Paris, France.

Pharmacie, Institut Gustave Roussy, Villejuif, France.

出版信息

J Oncol Pharm Pract. 2022 Mar;28(2):337-342. doi: 10.1177/1078155221991200. Epub 2021 Jan 31.

DOI:10.1177/1078155221991200
PMID:33522386
Abstract

BACKGROUND

Imatinib is a protein-tyrosine kinase inhibitor which is currently only commercially available as a tablet dosage form in the strength of 100mg and 400mg. The elaboration of new oral liquid formulations is suitable in pediatrics and for patients who have difficulties to swallow, notably in the absence of commercial forms. This enables the adaptation of dosage and secure the administration.

OBJECTIVES

The formulation of an oral pediatric solution of imatinib at a concentration of 30 mg/mL and the evaluation of its stability for the treatment of pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia.

METHODS

The physicochemical stability parameters: appearance, pH, osmolality, and drug content of formulation were evaluated for 30 days when stored at 2-8°C. Concentration of solution was measured with a validated method using high performance liquid chromatography (HPLC) coupled with an absorbance UV detector. Equally, microbiological stability was performed.

RESULTS

The remaining imatinib concentration was at least 95% of the initial concentration after 30 days stored in fridge temperature. No changes were observed regarding the physical properties of the formulation during the study period.

CONCLUSIONS

The stability study showed that the imatinib oral solution at a concentration of 30 mg/mL provides an alternative option at the commercial tablet dosage forms for pediatric patients and patients who have difficulties to swallow.

摘要

背景

伊马替尼是一种蛋白酪氨酸激酶抑制剂,目前仅以 100mg 和 400mg 片剂形式在商业上销售。新的口服液体制剂的研制适用于儿科和吞咽困难的患者,特别是在没有商业制剂的情况下。这使得剂量能够得到调整,并确保了给药的安全性。

目的

研制伊马替尼的口服儿科混悬液,浓度为 30mg/mL,并评估其在治疗费城染色体阳性慢性髓性白血病的儿科患者中的稳定性。

方法

在 2-8°C 下储存 30 天时,评估制剂的物理化学稳定性参数:外观、pH 值、渗透压和药物含量。使用经验证的高效液相色谱法(HPLC)结合紫外吸收检测器测定溶液的浓度。同样进行了微生物稳定性测试。

结果

在冰箱温度下储存 30 天后,伊马替尼的剩余浓度至少为初始浓度的 95%。在研究期间,制剂的物理性质没有观察到任何变化。

结论

稳定性研究表明,浓度为 30mg/mL 的伊马替尼口服溶液为儿科患者和吞咽困难的患者提供了一种替代商业片剂剂型的选择。

相似文献

1
Design and stability of pediatric oral formulation of imatinib.儿童用伊马替尼口服制剂的设计与稳定性。
J Oncol Pharm Pract. 2022 Mar;28(2):337-342. doi: 10.1177/1078155221991200. Epub 2021 Jan 31.
2
Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspensions.厄洛替尼、拉帕替尼和伊马替尼临时配制口服混悬液的稳定性。
Am J Health Syst Pharm. 2016 Sep 1;73(17):1331-7. doi: 10.2146/ajhp150581.
3
Stability of cilazapril in pediatric oral suspensions prepared from commercially available tablet dosage forms.西拉普利在由市售片剂剂型制备的儿科口服混悬液中的稳定性。
Acta Pol Pharm. 2014 Jul-Aug;71(4):661-6.
4
Stability of dapsone in two oral liquid dosage forms.氨苯砜在两种口服液体制剂中的稳定性。
Ann Pharmacother. 2000 Jul-Aug;34(7-8):848-50. doi: 10.1345/aph.19273.
5
Pediatric drugs--a review of commercially available oral formulations.儿科药物——市售口服制剂综述
J Pharm Sci. 2008 May;97(5):1731-74. doi: 10.1002/jps.21101.
6
Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.卡托普利速释口崩片替代制剂与口服液体制剂的稳定性比较。
Clin Ther. 2012 Nov;34(11):2221-9. doi: 10.1016/j.clinthera.2012.10.005.
7
The stability of quetiapine oral suspension compounded from commercially available tablets.市售片剂制备的喹硫平口服混悬液的稳定性。
PLoS One. 2021 Aug 10;16(8):e0255963. doi: 10.1371/journal.pone.0255963. eCollection 2021.
8
Physicochemical and Microbiological Stability of Compounded Metronidazole Suspensions in PCCA SuspendIt.PCCA SuspendIt 中配制的甲硝唑混悬液的理化和微生物稳定性。
Int J Pharm Compd. 2021 Mar-Apr;25(2):169-175.
9
Extemporaneous benznidazole oral suspension prepared from commercially available tablets for treatment of Chagas disease in paediatric patients.由市售片剂制备的即配苯硝唑口服混悬液用于治疗小儿恰加斯病。
Trop Med Int Health. 2015 Jul;20(7):864-70. doi: 10.1111/tmi.12508. Epub 2015 Apr 6.
10
Formulation and Stability Study of Omeprazole Oral Liquid Suspension for Pediatric Patients.儿童用奥美拉唑口服混悬液的处方及稳定性研究
Hosp Pharm. 2020 Oct;55(5):314-322. doi: 10.1177/0018578719844704. Epub 2019 Apr 25.

引用本文的文献

1
Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease.芦可替尼口服液在儿童激素耐药性急性移植物抗宿主病中的理化稳定性研究。
ScientificWorldJournal. 2022 Jun 2;2022:1931118. doi: 10.1155/2022/1931118. eCollection 2022.
2
Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update.儿童用复方非无菌制剂和美国食品药品监督管理局批准的市售液体产品:北美最新情况
Pharmaceutics. 2022 May 10;14(5):1032. doi: 10.3390/pharmaceutics14051032.